{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:26:58Z","timestamp":1793964418500,"version":"4.8.0"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, largely driven by metastatic disease. Increasing evidence suggests that metastasis is dictated by tumor-secreted factors that shape the microenvironment of target organs leading to the formation of the pre-metastatic niche (PMN) and resultant metastatic niche and tumor microenvironment (TME). Tumor-derived factors, including extracellular vesicles, cytokines, and integrins, orchestrate vascular remodeling, immune suppression, and stromal reprogramming in distant organs prior to tumor cell arrival. While many of these processes are shared, the liver develops a highly tolerogenic and immunosuppressive niche characterized by myeloid cell accumulation, T-cell depletion, and systemic immune dampening. In contrast, the lung exhibits a more inflammatory and immune-reactive microenvironment, with enhanced lymphocyte activation but concurrent neutrophil-driven immunosuppression. These differences translate into clinically meaningful disparities in immunotherapy outcomes, with liver metastasis consistently associated with resistance to ICIs, whereas lung metastasis demonstrates relatively improved responses. This review examines the mechanisms underlying PMN formation in CRC, with a particular focus on the liver and lung, and explores how their distinct immune landscapes influence response to immune checkpoint inhibitors (ICIs). It also evaluates the current therapeutic strategies aimed at overcoming organ-specific resistance, including combination immunotherapies, anti-angiogenic agents, targeted therapies, and TME-modulating approaches. Finally, we highlight key limitations in existing evidence and propose future directions, emphasizing the need for organ-specific therapeutic strategies and clinical trial designs. A deeper understanding of PMN biology and organ-dependent immune regulation may enable more effective, tailored treatments for metastatic CRC.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1838169","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:44:45Z","timestamp":1779342285000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Organ-specific pre-metastatic and metastatic niches in colorectal cancer: \u201cdiscrepancy in response to immune checkpoint inhibitors in liver and lung metastasis\u201d"],"prefix":"10.3389","volume":"17","author":[{"given":"Mohamad","family":"Mourad","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hematology\/Oncology Division, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layal","family":"Al Mahmasani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hematology\/Oncology Division, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura","family":"Abbas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hematology\/Oncology Division, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shamseddine","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hematology\/Oncology Division, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2605","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/s0140-6736(00)49915-0","article-title":"The distribution of secondary growths in cancer of the breast. 1889","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051130","article-title":"Tumor microenvironment in metastatic colorectal cancer: The arbitrator in patients' outcome","volume":"13","author":"Galindo-Pumari\u00f1o","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1677481","article-title":"Deciphering organotropism reveals therapeutic targets in metastasis","volume":"13","author":"Bautista","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1030147","article-title":"The effect of organ-specific tumor microenvironments on response patterns to immunotherapy","volume":"13","author":"Conway","year":"2022","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae013","article-title":"The efficacy of immune checkpoint inhibitors in microsatellite stable colorectal cancer: A systematic review","volume":"29","author":"Guven","year":"2024","journal-title":"Oncologist"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1403533","article-title":"Immune checkpoint inhibitors in colorectal cancer: limitation and challenges","volume":"15","author":"Yan","year":"2024","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae152","article-title":"Predictors of response to immunotherapy in colorectal cancer","volume":"29","author":"Gonz\u00e1lez-Montero","year":"2024","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/1078-0432.ccr-21-1193","article-title":"The liver-immunity nexus and cancer immunotherapy","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.1038\/s41467-018-07810-w","article-title":"Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis","volume":"9","author":"Zeng","year":"2018","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.04.013","article-title":"Mucosal immune responses to infection and vaccination in the respiratory tract","volume":"55","author":"Mettelman","year":"2022","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32090493","article-title":"Tumor immune microenvironment and current status of immune checkpoint inhibitor therapy in colorectal cancer liver metastasis","volume":"32","author":"Cao","year":"2025","journal-title":"Curr Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1367373","article-title":"Extracellular vesicle-mediated pre-metastatic niche formation via altering host microenvironments","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-019-0995-1","article-title":"Effects of exosomes on pre-metastatic niche formation in tumors","volume":"18","author":"Guo","year":"2019","journal-title":"Mol Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.devcel.2019.01.014","article-title":"Studying the fate of tumor extracellular vesicles at high spatiotemporal resolution using the zebrafish embryo","volume":"48","author":"Hyenne","year":"2019","journal-title":"Dev Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccr.2008.11.012","article-title":"Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche","volume":"15","author":"Erler","year":"2009","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nature15756","article-title":"Tumour exosome integrins determine organotropic metastasis","volume":"527","author":"Hoshino","year":"2015","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature04186","article-title":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","volume":"438","author":"Kaplan","year":"2005","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00172","article-title":"MDSCs: Key criminals of tumor pre-metastatic niche formation","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-024-01937-7","article-title":"Pre-metastatic niche: formation, characteristics and therapeutic implication","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12943-024-02107-7","article-title":"Neutrophils in the premetastatic niche: key functions and therapeutic directions","volume":"23","author":"Jia","year":"2024","journal-title":"Mol Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2016.5","article-title":"Immunological functions of liver sinusoidal endothelial cells","volume":"13","author":"Knolle","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2015.112","article-title":"Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells","volume":"13","author":"Horst","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgy115","article-title":"Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis","volume":"39","author":"Shao","year":"2018","journal-title":"Carcinogenesis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-020-00991-2","article-title":"Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer","volume":"13","author":"Zhao","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13062-025-00623-0","article-title":"Colon cancer exosome-associated HSP90B1 initiates pre-metastatic niche formation in the liver by polarizing M1 macrophage into M2 phenotype","volume":"20","author":"Li","year":"2025","journal-title":"Biol Direct"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215795","article-title":"Dual inhibition of TGF\u03b2 signaling and CSF1\/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1","volume":"543","author":"Chen","year":"2022","journal-title":"Cancer Lett"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.734351","article-title":"Exosome-derived ADAM17 promotes liver metastasis in colorectal cancer","volume":"12","author":"Sun","year":"2021","journal-title":"Front Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41419-019-1922-5","article-title":"The mechanism of the premetastatic niche facilitating colorectal cancer liver metastasis generated from myeloid-derived suppressor cells induced by the S1PR1-STAT3 signaling pathway","volume":"10","author":"Lin","year":"2019","journal-title":"Cell Death Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41392-023-01384-w","article-title":"Colorectal cancer-derived extracellular vesicles induce liver premetastatic immunosuppressive niche formation to promote tumor early liver metastasis","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-16-3199","article-title":"CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer","volume":"77","author":"Wang","year":"2017","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27378","article-title":"Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1\/CXCR4-dependent neutrophil recruitment in mice","volume":"61","author":"Seubert","year":"2015","journal-title":"Hepatology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12967-025-06334-4","article-title":"Colorectal cancer cells-derived exosomal miR-188-3p promotes liver metastasis by creating a pre-metastatic niche via activation of hepatic stellate cells","volume":"23","author":"Li","year":"2025","journal-title":"J Transl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194755","article-title":"Tumor-associated neutrophils in colorectal cancer development, progression and immunotherapy","volume":"14","author":"Zheng","year":"2022","journal-title":"Cancers"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70248","article-title":"Targeted lung premetastasis niche: mechanisms, strategies, and application","volume":"6","author":"Cao","year":"2025","journal-title":"MedComm (2020)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.733627","article-title":"Pre-metastatic niche formation in different organs induced by tumor extracellular vesicles","volume":"9","author":"Dong","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.06.021","article-title":"Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating alveolar epithelial TLR3 to recruit neutrophils","volume":"30","author":"Liu","year":"2016","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41419-022-04825-6","article-title":"Exosomal miR-146a-5p and miR-155-5p promote CXCL12\/CXCR7-induced metastasis of colorectal cancer by crosstalk with cancer-associated fibroblasts","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"7316","DOI":"10.1038\/s41467-022-35096-6","article-title":"Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer","volume":"13","author":"Sui","year":"2022","journal-title":"Nat Commun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.018","article-title":"Immune determinants of the pre-metastatic niche","volume":"41","author":"Patras","year":"2023","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-0520","article-title":"Loss of SMAD4 promotes lung metastasis of colorectal cancer by accumulation of CCR1+ tumor-associated neutrophils through CCL15-CCR1 axis","volume":"23","author":"Yamamoto","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41467-025-66897-0","article-title":"Residual tumor cells after insufficient radiofrequency ablation promote lung metastasis by educating CD177(hi)PAD4(hi) neutrophils","volume":"17","author":"Huang","year":"2025","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00219","article-title":"Interactions in the (pre)metastatic niche support metastasis formation","volume":"9","author":"Doglioni","year":"2019","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e230400","DOI":"10.1001\/jamanetworkopen.2023.0400","article-title":"Association between survival and metastatic site in mismatch repair\u2013deficient metastatic colorectal cancer treated with first-line pembrolizumab","volume":"6","author":"Saberzadeh-Ardestani","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","article-title":"Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer","volume":"13","author":"Qi","year":"2022","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12186","article-title":"Highly-metastatic colorectal cancer cell released miR-181a-5p-rich extracellular vesicles promote liver metastasis by activating hepatic stellate cells and remodeling the tumour microenvironment","volume":"11","author":"Zhao","year":"2022","journal-title":"J Extracell Vesicles"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13046-024-02991-3","article-title":"Tumor-derived exosomal ADAM17 promotes pre-metastatic niche formation by enhancing vascular permeability in colorectal cancer","volume":"43","author":"Li","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci Transl Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02034-0","article-title":"PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer","volume":"23","author":"Li","year":"2025","journal-title":"Cell Commun Signal"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6074.tumimm21-p061","article-title":"Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy","volume":"118","author":"Ho","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-24-1074","article-title":"Liver metastases license neutrophils through IL1 to potentiate cancer progression","volume":"13","author":"Pearson","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41420-021-00621-x","article-title":"Proteomic signatures of myeloid derived suppressor cells from liver and lung metastases reveal functional divergence and potential therapeutic targets","volume":"7","author":"DaSilva","year":"2021","journal-title":"Cell Death Discov"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.18416","article-title":"Clinical response to immunotherapy targeting programmed cell death receptor 1\/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-23-0212","article-title":"Peritumoral immune-suppressive mechanisms impede intratumoral lymphocyte infiltration into colorectal cancer liver versus lung metastases","volume":"3","author":"Ye","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00428-023-03577-8","article-title":"Tertiary lymphoid structures in pulmonary metastases of microsatellite stable colorectal cancer","volume":"483","author":"Karjula","year":"2023","journal-title":"Virchows Arch"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246206","article-title":"The colorectal cancer tumor microenvironment and its impact on liver and lung metastasis","volume":"13","author":"Chandra","year":"2021","journal-title":"Cancers"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051434","article-title":"The resection rate of synchronously detected liver and lung metastasis from colorectal cancer is low\u2014a national registry-based study","volume":"15","author":"Engstrand","year":"2023","journal-title":"Cancers"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.19025","article-title":"Microsatellite stable colorectal liver metastases\u2014understanding the mechanisms of immune resistance","volume":"4","author":"Gholami","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113433","article-title":"Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting","volume":"196","author":"Saberzadeh-Ardestani","year":"2024","journal-title":"Eur J Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113437","article-title":"Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases","volume":"196","author":"Fakih","year":"2024","journal-title":"Eur J Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.46094","article-title":"Liver metastases and immune checkpoint inhibitor efficacy in patients with refractory metastatic colorectal cancer: a secondary analysis of a randomized clinical trial","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.04.014","article-title":"LBA-4 results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)","volume":"34","author":"Bullock","year":"2023","journal-title":"Ann Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability\u2013high metastatic colorectal cancer","volume":"391","author":"Andr\u00e9","year":"2024","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.4_suppl.lba248","article-title":"Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: the phase 3, randomized KEYFORM-007 study","volume":"43","author":"Segal","year":"2025","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.4_suppl.tps278","article-title":"RELATIVITY-123: a phase 3, randomized, open-label study of nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) versus regorafenib or trifluridine + tipiracil (TAS-102) in later-line metastatic colorectal cancer (mCRC)","volume":"41","author":"Feeney","year":"2023","journal-title":"J Clin Oncol"},{"key":"B73","unstructured":"A study of nivolumab-relatlimab fixed-dose combination versus regorafenib or TAS-102 in participants with later-lines of metastatic colorectal cancer (RELATIVITY-123)\n          \n          \n          2025"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008689","article-title":"Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"12","author":"Overman","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicenter, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"3569\u2013","DOI":"10.1200\/jco.2024.42.16_suppl.3569","article-title":"First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: a phase 2\/3 study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02813-1","article-title":"Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005332","article-title":"Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)","volume":"10","author":"Johnson","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-0090","article-title":"A phase II study of potentiation of pembrolizumab with binimetinib and bevacizumab in refractory microsatellite-stable colorectal cancer","volume":"30","author":"Lentz","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7845","article-title":"Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial","volume":"9","author":"Fakih","year":"2023","journal-title":"JAMA Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/s41467-024-45960-2","article-title":"Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort","volume":"15","author":"Saeed","year":"2024","journal-title":"Nat Commun"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02736","article-title":"Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 study","volume":"42","author":"Kawazoe","year":"2024","journal-title":"J Clin Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)02025-2","article-title":"Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial","volume":"406","author":"Hecht","year":"2025","journal-title":"Lancet"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105508","article-title":"Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicenter, single-arm phase II study (ILOC)","volume":"10","author":"Seligmann","year":"2025","journal-title":"ESMO Open"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-026-02689-3","article-title":"RT-ICI therapy induces a distal immunometabolic axis that shapes systemic macrophage polarization and enhances local T cell immunity","volume":"24","author":"Ge","year":"2026","journal-title":"Cell Commun Signal"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2579\u2013","DOI":"10.1200\/jco.2019.37.15_suppl.2579","article-title":"MEDIPLEX: a phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC)","volume":"37","author":"Cassier","year":"2019","journal-title":"J Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14289","article-title":"Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours","volume":"86","author":"Mahalingam","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011284","article-title":"Phase 1b\/2 study of BMS-813160, a CCR2\/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer","volume":"14","author":"Le","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"v231","DOI":"10.1093\/annonc\/mdz246.090","article-title":"613P - phase I\/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer","volume":"30","author":"Halama","year":"2019","journal-title":"Ann Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03430-6","article-title":"First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors","volume":"72","author":"Bendell","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00446-6","article-title":"Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial","volume":"23","author":"Yamazaki","year":"2022","journal-title":"Lancet Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03916-0","article-title":"A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)","volume":"84","author":"Clarke","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3245-5","article-title":"A phase 1 study of anti-TGF\u03b2 receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors","volume":"79","author":"Tolcher","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5706","article-title":"Exosomal integrins in tumor progression, treatment and clinical prediction (review)","volume":"65","author":"Shen","year":"2024","journal-title":"Int J Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/cells15010029","article-title":"Integrin-mediated TIMP1 signaling reprograms liver macrophages and accelerates colorectal cancer metastasis","volume":"15","author":"Liu","year":"2025","journal-title":"Cells"},{"key":"B97","doi-asserted-by":"publisher","first-page":"361ra138","DOI":"10.1126\/scitranslmed.aag1711","article-title":"Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps","volume":"8","author":"Park","year":"2016","journal-title":"Sci Transl Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1038\/s41467-018-07306-7","article-title":"Colorectal cancer liver metastatic growth depends on PAD4-driven citrullination of the extracellular matrix","volume":"9","author":"Yuzhalin","year":"2018","journal-title":"Nat Commun"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215333","article-title":"Neutrophils extracellular traps inhibition improves PD-1 blockade immunotherapy in colorectal cancer","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B100","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13046-025-03544-y","article-title":"The cGAS\u2013STING pathway in colorectal cancer: bridging innate immunity and therapeutic strategies","volume":"44","author":"Li","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1258691","article-title":"Immunotherapy with STING and TLR9 agonists promotes synergistic therapeutic efficacy with suppressed cancer-associated fibroblasts in colon carcinoma","volume":"14","author":"Hajiabadi","year":"2023","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02380-2","article-title":"TGF-\u03b2 builds a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1+ macrophages","volume":"57","author":"Henriques","year":"2025","journal-title":"Nat Genet"},{"key":"B103","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.clcc.2025.08.003","article-title":"Adjuvant anti-inflammatory therapy in postoperative colorectal cancer: A systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Lenz","year":"2025","journal-title":"Clin Colorectal Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1686071","article-title":"Organotropic metastasis in colorectal cancer: Integrating molecular pathways with therapeutic opportunities","volume":"16","author":"Jing","year":"2025","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/s12967-023-04460-5","article-title":"Metastasis organotropism in colorectal cancer: Advancing toward innovative therapies","volume":"21","author":"He","year":"2023","journal-title":"J Transl Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17060953","article-title":"Liver extracellular matrix in colorectal liver metastasis","volume":"17","author":"Morabito","year":"2025","journal-title":"Cancers"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3390\/biom13040689","article-title":"Implications of the organ-specific immune environment for immune priming effect of radiotherapy in metastatic setting","volume":"13","author":"Pierrard","year":"2023","journal-title":"Biomolecules"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1838169\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:44:49Z","timestamp":1779342289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1838169\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":107,"alternative-id":["10.3389\/fimmu.2026.1838169"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1838169","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1838169"}}